A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

NCT05601232 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Angiosarcoma

Interventions

RADIATION: BNCT

Sponsor

Stella Pharma Corporation

Collaborators

[object Object]